Maraviroc

Maraviroc, the active ingredient in Maraviroc, is a CCR5 antagonist presented as a tablet for oral use. It treats HIV-1 infection in treatment‑experienced patients with CCR5‑tropic virus.

GNH USA supplies Maraviroc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is used in antiretroviral therapy targeting CCR5‑tropic HIV‑1 infection. - HIV‑1 infection (treatment‑experienced, CCR5‑tropic virus): provides viral suppression when combined with other antiretrovirals.

Maraviroc may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Diarrhea: loose stools. - Upper respiratory infection: cold‑like symptoms. - Fatigue: feeling unusually tired. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury. - Severe allergic reaction: swelling, breathing difficulty. - Depression or mood changes: new or worsening symptoms. - Cardiovascular events: chest pain or arrhythmia. - Immune reconstitution syndrome: inflammatory response after immune recovery.

Before prescribing Maraviroc, clinicians should consider several safety measures. - Assess CCR5 tropism: confirm virus uses CCR5 before initiation. - Monitor liver function: periodic tests recommended. - Review concomitant medications: especially CYP3A4 inhibitors or inducers. - Educate patients on signs of severe reactions: rash, hepatitis, mood changes. - Avoid use in patients with known hypersensitivity to maraviroc. - Store at below 25°C: keep in the original pack, protect from moisture.

Maraviroc interacts with several drug classes; careful management is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin): may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids containing aluminum or magnesium hydroxide: can lower absorption.

Moderate Interactions (Monitor Closely): - Other antiretrovirals (e.g., protease inhibitors): may require dose adjustment. - Statins (e.g., simvastatin): increased risk of myopathy. - Hormonal contraceptives: possible reduced effectiveness.